ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising new findings based on a previously published clinical trial of company’s proprietary Niagen® ingredient (patented nicotinamide riboside or NR), which was supported by the ChromaDex External Research Program (CERP™). The new study, published in the peer-reviewed journal Aging+Cell, was led by Dr. Christopher R. Martens, Department of Kinesiology & Applied Physiology, University of Delaware, USA, in collaboration with scientists from the National Institute on Aging (NIA). The study investigated whether NR would positively augment nicotinamide adenine dinucleotide (NAD+) levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles (NEVs) found in blood plasma. NEVs are nano-sized particles that are released by neurons in the central nervous system, including the brain, and circulate in blood plasma. They can contain RNA, DNA, and/or proteins that provide information relating to the metabolism of their tissue of origin, and serve as signaling molecules between various cells, tissues, or organs. Some scientists are investigating extracellular vesicles as biomarkers of disease development and progression. The present study demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
Dec 27, 2022
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers